Optimistic about the company's development prospects, DUALITYBIO-B (09606) directors and senior management make voluntary lock-up commitments.

DUALITYBIO-B (09606) announces that the company's directors and senior management are full of confidence in the company's long-term value and future development prospects. The board of directors has been informed that, based on the above confidence, Dr. Zhu Zhongyuan, chairman of the board, executive director and chief executive officer; Mr. Zhang Shaoren, executive director and chief financial officer; Dr. Hua Haiqing, executive director, senior vice president and head of drug discovery; Dr. Qiu Yang, chief scientific officer and general manager of Dualitybio Inc.; Dr. Mou Hua, global chief medical officer; Ms. Si Wen, executive director of human resources; Mr. Yu Xin, vice president and head of regulatory affairs; Ms. Zhou Lan, vice president of business strategy; and Ms. Yuan Jiali, vice president, head of legal and compliance and joint company secretary, have voluntarily undertaken not to initiate, or instruct others to initiate, any transaction involving the sale or other disposal of shares of the company directly or indirectly beneficially owned by them, including any shares acquired upon exercise of share options during the lock-up period, for a period of six months commencing from October 29, 2026 (i.e., from October 29, 2026 to April 28, 2027, inclusive).